Zobrazeno 1 - 10
of 37
pro vyhledávání: '"H. Madariaga"'
Autor:
MV Gutierrez-Ardila, Jm Reyes, H Madariaga, W Otero, R Guzman, J Izquierdo, M Abello, P Velez, D Castillo, D Ponce de Leon, T Lukic, L Amador
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 22:787-794
To evaluate work productivity of adult Latin American patients with rheumatoid arthritis (RA) treated with tofacitinib and biological disease-modifying anti-rheumatic drugs (bDMARDs) measured by the Work Productivity and Activity Impairment (WPAI) in
Publikováno v:
Medicentro, Vol 19, Iss 1, Pp 25-27 (2014)
Solanum melongena es una planta que se emplea principalmente con fines alimenticios. Diferentes estudios han informado su utilidad como hipolipemiante, antinflamatorio, antitumoral, entre otros. En estudios experimentales realizados en roedores, some
Externí odkaz:
https://doaj.org/article/c559e39428d049a3bbc394ba1e417dd1
Autor:
R. Guzman, J Izquierdo, J. Reyes, L. Amador, M Abello, W Otero, P Velez, Tatjana Lukic, D Castillo, MV Gutierrez, Dario Ponce de Leon, H. Madariaga
Objective: To describe the efficacy, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) treated with tofacitini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bf6fb31a58ba598062a9b9ae971a205
https://doi.org/10.21203/rs.3.rs-828468/v1
https://doi.org/10.21203/rs.3.rs-828468/v1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D. Ponce de Leon, A. Ebrahim, Lori Stockert, F. Irazoque-Palazuelos, Lisy Wang, Ming-Ann Hsu, K. Santana, H. Madariaga, David Gruben, Gustavo Citera, R. Jain, R. Guzman
Publikováno v:
Annals of the Rheumatic Diseases. 79:318-319
Background:Depression/anxiety are common in RA pts. SF-36 MCS ≤38 can identify probable major depressive disorder and/or probable generalised anxiety disorder (pMDD/pGAD) in RA pts. Tofacitinib is an oral JAK inhibitor for the treatment of RA.Objec
Publikováno v:
Value in Health. 24:S138
Publikováno v:
Value in Health. 24:S143
Publikováno v:
Value in Health. 24:S142
Autor:
Enrique R. Soriano, D. Ponce de Leon, Emilce Edith Schneeberger, Harry Shi, Gustavo Citera, Mario H. Cardiel, H. Madariaga, Daniela Graham, Thijs Hendrikx, Oswaldo Castañeda
Publikováno v:
FRIDAY, 15 JUNE 2018.
Background Non-alcoholic fatty liver disease, characterised by hepatic steatosis (HS), is a major cause of chronic liver disease in many countries. Limited data are available on liver enzyme elevation in patients (pts) with HS who are receiving medic
Autor:
LJ Elizondo, Marcia Pinheiro, L Gόrriz, D. Ponce de Leon, LF Medina, Emilce Edith Schneeberger, Rdn Giorgi, JC Sarmiento-Monroy, A Salas, B Garro, RD Mantilla, H. Madariaga, JB Zacariaz
Publikováno v:
Abstracts Accepted for Publication.
Background Tofacitinib is an oral JAK inhibitor for the treatment of RA. Tofacitinib can be given as monotherapy or with csDMARDs. Published data on real world (RW) tofacitinib use in Latin America (LA) are limited. We characterise the patient (pt) p